Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod.

David OJ, Berwick A, Pezous N, Lang M, Tiel-Wilck K, Ziemssen T, Li P, Hara H, Schmouder R.

Clin Pharmacol Drug Dev. 2018 Feb;7(2):217-221. doi: 10.1002/cpdd.424. Epub 2017 Dec 19.

2.

Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.

Freidel M, Tiel-Wilck K, Schreiber H, Prechtl A, Essner U, Lang M.

Acta Neurol Scand. 2015 Jan;131(1):9-16. doi: 10.1111/ane.12287. Epub 2014 Sep 11.

PMID:
25208898
3.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

4.

[Direct costs for Parkinson's treatment in private neurology practices in Berlin].

Ehret R, Balzer-Geldsetzer M, Reese JP, Dodel I, Becker E, Christopher A, Friedrich H, Kraemer S, Lüer W, Müngersdorf M, Puzich R, Rohr A, Schultes-Platzek I, Siefjediers V, Tiel-Wilck K, Oertel WH, Dodel R.

Nervenarzt. 2009 Apr;80(4):452-8. doi: 10.1007/s00115-009-2671-y. German.

PMID:
19252890
5.

The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation Study.

Scherer P, Penner IK, Rohr A, Boldt H, Ringel I, Wilke-Burger H, Burger-Deinerth E, Isakowitsch K, Zimmermann M, Zahrnt S, Hauser R, Hilbert K, Tiel-Wilck K, Anvari K, Behringer A, Peglau I, Friedrich H, Plenio A, Benesch G, Ehret R, Nippert I, Finke G, Schulz I, Bergtholdt B, Breitkopf S, Kaskel P, Reischies F, Kugler J.

Mult Scler. 2007 Apr;13(3):402-11. Epub 2007 Jan 29.

PMID:
17439910
6.

Short-term efficacy of Epley's manoeuvre: a double-blind randomised trial.

von Brevern M, Seelig T, Radtke A, Tiel-Wilck K, Neuhauser H, Lempert T.

J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):980-2. Epub 2006 Mar 20.

7.

Self-treatment of benign paroxysmal positional vertigo: Semont maneuver vs Epley procedure.

Radtke A, von Brevern M, Tiel-Wilck K, Mainz-Perchalla A, Neuhauser H, Lempert T.

Neurology. 2004 Jul 13;63(1):150-2.

PMID:
15249626
8.

Benign paroxysmal positional vertigo: current status of medical management.

von Brevern M, Lezius F, Tiel-Wilck K, Radtke A, Lempert T.

Otolaryngol Head Neck Surg. 2004 Mar;130(3):381-2. No abstract available.

PMID:
15054387
9.

Is visual field constriction in epilepsy patients treated with vigabatrin reversible?

Schmidt T, Rüther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B.

J Neurol. 2002 Aug;249(8):1066-71.

PMID:
12195456
10.

Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study.

Schmitz B, Schmidt T, Jokiel B, Pfeiffer S, Tiel-Wilck K, Rüther K.

J Neurol. 2002 Apr;249(4):469-75.

PMID:
11967655
11.

A positional maneuver for treatment of horizontal-canal benign positional vertigo.

Lempert T, Tiel-Wilck K.

Laryngoscope. 1996 Apr;106(4):476-8.

PMID:
8614224
12.

[Migraine: differential diagnosis in episodic vertigo].

Lempert T, Menzhausen L, Tiel-Wilck K.

Nervenarzt. 1993 Feb;64(2):121-6. German.

PMID:
8450894

Supplemental Content

Loading ...
Support Center